Medtronic Plc won U.S. approval on Wednesday for an "artificial pancreas" that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day. The U.S. Food and Drug Administration, in its approval of the device, the MiniMed 670G, hailed it as a breakthrough. The device offers type 1 diabetics "greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin," Dr. Jeffrey Shuren, director of the FDA's medical device division, said in a statement.
- Business Wire•2 days ago
Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2016 on November 3, 2016 after the close of the financial markets.
- Business Wire•17 days ago
Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced the first patient has completed the feasibility study of the Omnipod Horizon™ Automated Glucose Control System .
Insulet Corporation (PODD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||38.15 x 100|
|Day's Range||39.32 - 42.65|
|52wk Range||23.94 - 45.60|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-35.81|
|Avg Vol (3m)||556,957|
|Dividend & Yield||N/A (N/A)|